Mural Oncology (NASDAQ:MURA) Cut to “Equal Weight” at Morgan Stanley

Morgan Stanley cut shares of Mural Oncology (NASDAQ:MURA) from an overweight rating to an equal weight rating in a report published on Tuesday, Marketbeat reports.

A number of other research analysts also recently commented on the stock. Raymond James downgraded shares of Mural Oncology from a “strong-buy” rating to an “outperform” rating and set a $18.00 price objective on the stock. in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Mural Oncology in a report on Wednesday, March 12th. Finally, Jones Trading reiterated a “hold” rating on shares of Mural Oncology in a report on Tuesday. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, Mural Oncology presently has an average rating of “Moderate Buy” and an average price target of $13.00.

Mural Oncology Trading Up 1.5 %

Shares of MURA stock opened at $1.35 on Tuesday. The firm has a fifty day simple moving average of $3.77 and a 200-day simple moving average of $3.58. The company has a market capitalization of $23.26 million, a PE ratio of -0.15 and a beta of 3.66. Mural Oncology has a twelve month low of $1.28 and a twelve month high of $5.12.

Mural Oncology (NASDAQ:MURA) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($2.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.96) by ($0.05). During the same quarter in the prior year, the firm earned ($3.57) EPS. Equities research analysts predict that Mural Oncology will post -7.54 EPS for the current year.

Institutional Investors Weigh In On Mural Oncology

Institutional investors and hedge funds have recently bought and sold shares of the business. Commerce Bank acquired a new position in Mural Oncology in the third quarter valued at approximately $39,000. FMR LLC lifted its holdings in shares of Mural Oncology by 124.7% in the 3rd quarter. FMR LLC now owns 20,580 shares of the company’s stock worth $64,000 after purchasing an additional 11,423 shares during the last quarter. Jane Street Group LLC acquired a new position in Mural Oncology during the 4th quarter valued at approximately $68,000. Two Sigma Advisers LP acquired a new position in Mural Oncology during the 4th quarter valued at approximately $84,000. Finally, Bridgeway Capital Management LLC bought a new position in Mural Oncology during the 4th quarter worth $94,000. Institutional investors and hedge funds own 80.21% of the company’s stock.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.